DDInter1435 DDInter1026
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high
Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.
Larotrectinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Larotrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Larotrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Larotrectinib {u} may lead to a major life threatening interaction when taken with {v} Pimozide
Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Larotrectinib may lead to a major life threatening interaction when taken with Pimozide